{"schema_version":"secwatch.filing_event.v1","accession":"0001048477-25-000088","form_type":"8-K","ticker":"BMRN","cik":"0001048477","company_name":"BIOMARIN PHARMACEUTICAL INC","filed_at":"2025-08-04T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.197194+00:00","generated_at":"2026-05-17T21:19:47.377928+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"BioMarin Q2 revenue $825M (+16% Y/Y); GAAP EPS $1.23 (+124%); raises full-year guidance","bullets":["Total revenue $825M, +16% Y/Y; GAAP net income $241M (vs $107M) and diluted EPS $1.23 (+124%).","Non-GAAP diluted EPS $1.44 (+50%); N-GAAP operating margin 39.9% (up 8.7pp Y/Y).","VOXZOGO revenue $221M (+20%) and Enzyme Therapies $555M (+15%); KUVAN down 7% to $27M.","Raised FY2025 guidance for total revenues, non-GAAP operating margin, and non-GAAP diluted EPS.","Completed Inozyme acquisition (July); BMN 333 (achondroplasia) Phase 2/3 to start 1H'26; BMN 390 discontinued."],"urls":{"canonical":"https://secwatch.observer/filing/0001048477-25-000088","json":"https://secwatch.observer/filing/0001048477-25-000088.json","markdown":"https://secwatch.observer/filing/0001048477-25-000088.md","text":"https://secwatch.observer/filing/0001048477-25-000088.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/0001048477-25-000088-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1048477/000104847725000088/bmrn-20250804.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T21:19:47.377928+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}